

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1625
COLLINGWOOD, STEPHEN PAUL ET AL. EXAMINER: CHANG, CELIA C
INTERNATIONAL APPLICATION NO: PCT/EP2004/006795
FILED: JUNE 23, 2004
U.S. APPLICATION NO: 10/561366
35 USC §371 DATE: MAY 15, 2006
FOR: PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS
FOR THE MUSCARINIC M3 RECEPTOR

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed December 19, 2005.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.
§1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Cozette M. McAvoy
Attorney for Applicant
Reg. No. 60,457

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273

Date: *26 May 2010*